| P50 | author | Pellegrino Musto | Q37841576 |
| | Antonino Neri | Q56850455 |
| | Katia Todoerti | Q39052018 |
| | Vittorio Simeon | Q42069384 |
| P2860 | cites work | Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine | Q26799238 |
| | Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. | Q27691802 |
| | Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia | Q33331137 |
| | Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia | Q33343818 |
| | Bortezomib is an efficient agent in plasma cell leukemias | Q33364213 |
| | Thirty patients with primary plasma cell leukemia: a single center experience | Q33379649 |
| | How I treat plasma cell leukemia | Q33402555 |
| | Primary plasma cell leukaemia | Q33490175 |
| | Plasma cell leukaemia and other aggressive plasma cell malignancies | Q33708734 |
| | Primary plasma cell leukemia and autologous stem cell transplantation | Q33829100 |
| | Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group | Q33956990 |
| | Trends in survival of patients with primary plasma cell leukemia: a population-based analysis | Q34019590 |
| | Primary plasma cell leukaemia: a report of 18 cases | Q34134838 |
| | Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. | Q34173892 |
| | Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. | Q34479418 |
| | Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia | Q34632925 |
| | Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia. | Q35235334 |
| | Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research | Q35742685 |
| | Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature | Q36082616 |
| | Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols | Q36185955 |
| | Clinical Features and Outcomes of Plasma Cell Leukemia: A Single-Institution Experience in the era of Novel Agents | Q36331788 |
| | Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation | Q36414422 |
| | Genetic aberrations and survival in plasma cell leukemia | Q37486780 |
| | Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. | Q37724272 |
| | Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens | Q37777839 |
| | Plasma cell leukemia: concepts and management | Q37810276 |
| | Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia. | Q53262828 |
| | Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization | Q53709825 |
| | Plasma cell leukemia. Report on 17 cases | Q53817942 |
| | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | Q57904272 |
| | Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience | Q58051878 |
| | Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles | Q58321395 |
| | Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma | Q58455735 |
| | Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia | Q60649178 |
| | Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension | Q64050288 |
| | Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hé | Q73396499 |
| | Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center | Q79839194 |
| | VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia | Q80059530 |
| | Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement | Q80203563 |
| | Efficacy and safety of bortezomib in patients with plasma cell leukemia | Q80238489 |
| | Bortezomib is effective in primary plasma cell leukemia | Q80243154 |
| | Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia | Q80573613 |
| | Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia | Q80573616 |
| | Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment | Q80735461 |
| | Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia | Q81435934 |
| | Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia | Q84421071 |
| | Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004 | Q84820019 |
| | Allogeneic stem cell transplantation for multiple myeloma | Q85295735 |
| | Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients | Q85330185 |
| | Novel Agents for the Treatment of Primary Plasma-Cell Leukemia: Lights and Shadows | Q86565905 |
| | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia | Q87997837 |
| | Primary plasma cell leukemia in the era of new drugs: has something changed? | Q37896333 |
| | Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience | Q37911050 |
| | Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. | Q38082246 |
| | Stringent Complete Remission of Primary Plasma Cell Leukemia with Reduced-dose Bortezomib, Lenalidomide and Dexamethasone: A Case Report and Review of the Literature | Q38111232 |
| | Plasma cell leukemia: from biology to treatment | Q38380625 |
| | Frontline therapy of multiple myeloma. | Q38403316 |
| | Defining and treating high-risk multiple myeloma | Q38564926 |
| | Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group | Q38681463 |
| | Plasma cell leukemia: a report on 15 patients. | Q38774501 |
| | Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. | Q39430844 |
| | Plasma cell leukemia: an evaluation of response to therapy | Q39725181 |
| | Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. | Q40110567 |
| | Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation | Q40228702 |
| | Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma | Q41181074 |
| | Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia | Q42096911 |
| | Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen | Q42952891 |
| | Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record | Q43248537 |
| | Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy | Q43260441 |
| | Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy | Q43289813 |
| | Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia | Q43985644 |
| | Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma | Q44024556 |
| | Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia | Q44404066 |
| | Thalidomide Administration for the Treatment of Resistant Plasma Cell Leukemia | Q44441228 |
| | Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group | Q44559311 |
| | Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project | Q44638943 |
| | Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party | Q44962191 |
| | Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report | Q45009416 |
| | Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. | Q45392132 |
| | Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report. | Q45992461 |
| | Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation | Q46325674 |
| | A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China | Q46360537 |
| | Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. | Q46416585 |
| | Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia | Q46448690 |
| | Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia | Q46629184 |
| | Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia | Q46817722 |
| | Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib | Q46823524 |
| | Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? | Q46847841 |
| | Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia | Q46882603 |
| | Frequent upregulation of MYC in plasma cell leukemia | Q47934970 |
| | Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics | Q50538038 |
| | Primary plasma cell leukemia: a retrospective multicenter study of 73 patients | Q51514754 |
| | Plasma cell leukemia: a rare condition | Q51823792 |
| P433 | issue | 4 | |
| P921 | main subject | plasma cell leukemia | Q7201765 |
| P304 | page(s) | 19 | |
| P577 | publication date | 2016-04-01 | |
| P1433 | published in | Current Treatment Options in Oncology | Q3510796 |
| P1476 | title | Primary Plasma Cell Leukemia: Identity Card 2016. | |
| P478 | volume | 17 | |